XML 56 R41.htm IDEA: XBRL DOCUMENT
v3.25.1

SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($) $ in Thousands | 3 Months Ended
--- | ---
Mar. 31, 2025 | Mar. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total Revenue from Janssen Collaboration Agreement | $ 0 | $ 973
Related Party | Collaborative Arrangement | Janssen Pharmaceuticals, Inc. |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total Revenue from Janssen Collaboration Agreement |  | 973
Related Party | Over Time: | Collaborative Arrangement | Research and Development Services | Janssen Pharmaceuticals, Inc. |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total Revenue from Janssen Collaboration Agreement |  | 971
Related Party | Over Time: | Collaborative Arrangement | Clinical Supply Services | Janssen Pharmaceuticals, Inc. |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total Revenue from Janssen Collaboration Agreement |  | $ 2

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |